XML 50 R36.htm IDEA: XBRL DOCUMENT v3.26.1
FINANCIAL INSTRUMENTS (Tables)
6 Months Ended
Jun. 30, 2026
Fair Value Disclosures [Abstract]  
Schedule of Carrying Amount and Fair Value of the Long-Term Debt
At June 30, 2026, the carrying values and fair values of the Company’s financial assets and liabilities were as follows (in thousands):
Carrying ValueFair Value Measurements Using
Level 1Level 2Level 3
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:
Financial Assets:
Equity investments$7,750 $— $— $7,750 
Convertible notes receivable$2,500 $— $— $2,500 
Financial Liabilities:
   Acquisition-related contingent consideration$17,452 $— $— $17,452 
Financial Liabilities Measured at Amortized Cost:
   2.125% convertible senior notes due 2029 (1)
$282,124 $— $287,322 $— 
   Revolving Credit Facility$81,000 $— $81,000 $— 
(1) The closing price of the Company’s common stock as reported on the Nasdaq Global Select Market was $25.37 per share on June 30, 2026, compared to a conversion price of $39.56 per share. At June 30, 2026, as the conversion price was above the stock price, the requirements for conversion have not been met.
Schedule of Investments without Readily Determinable Fair Value The following investments have no readily determinable fair value and are recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments (in thousands):
Equity InvestmentsConvertible Notes ReceivableTotal
Balance at December 31, 2024
$15,877 $11,898 $27,775 
Purchases— 1,250 1,250 
Impairments(4,000)(7,000)(11,000)
Realized gain of prior investments (1)
4,189 1,674 5,863 
Settled investments (1)
(8,277)(5,322)(13,599)
Foreign currency adjustments(39)— (39)
Balance at December 31, 2025
7,750 2,500 10,250 
— No activity for the six months ended June 30, 2026 —
— — — 
Balance at June 30, 2026
$7,750 $2,500 $10,250 
(1) In conjunction with the GQ Bio Acquisition, the settlement of the Company’s prior equity investment and notes receivable were part of the fair value of consideration exchanged. Upon acquiring the remaining 81% ownership interest in GQ Bio, the Company remeasured its previously held equity interest to its acquisition-date fair value. The $4.2 million gain resulting from the equity investment was recognized as other, net within the condensed consolidated statement of operations. In settling the notes receivable, the Company recognized $1.7 million in interest income. These gains were included in the condensed consolidated statement of cash flows for the six months ended June 30, 2025 within other net gains.
Schedule of Key Assumptions used in the Valuation of Contingent Consideration
The following table includes the key assumptions used in the valuation of the Company’s contingent consideration:
Assumption
Ranges Utilized as of
June 30, 2026
Discount rates
7.6% to 8.1%
Probability of payment for remaining regulatory milestones
0%
Schedule of Change in Contingent Consideration Recorded at Fair Value using Level 3 Measurements
The change in the Company’s contingent consideration recorded at fair value using Level 3 measurements is as follows (in thousands):
Contingent Consideration
Fair Value
Balance at December 31, 2024
$20,241 
Fair value adjustments and accretion(2,175)
Balance at December 31, 2025
18,066 
   Fair value adjustments and accretion(614)
Balance at June 30, 2026
$17,452 
Schedule of Short-Term and Noncurrent Available-for-Sale Investments
The following summarizes the Company’s available-for-sale investments at June 30, 2026 and December 31, 2025 (in thousands):
June 30, 2026 Investments
CostGross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
(Level 2)
Current:
Commercial paper$27,158 $— $(24)$27,134 
Corporate bonds18,027 — (5)18,022 
          Total$45,185 $— $(29)$45,156 
December 31, 2025 Investments
CostGross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
(Level 2)
Current:
Commercial paper$54,971 $18 $(13)$54,976 
Corporate bonds24,881 22 — 24,903 
          Total$79,852 $40 $(13)$79,879